Results

FDA Approves Hibsago, the First Antisense Drug for Chronic Hepatitis B, With a Boxed Warning

GSK's bepirovirsen cleared 19 percent of adults in pooled phase 3 trials of a surface-antigen cure marker, but it carries warnings for liver flares and falling platelet counts.

Oct 22, 2026